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RESUMO
Avaliação a Médio Prazo do Controle de Fatores 
de Risco de Doença Cardiovascular em Coorte 
Prospectiva de Pacientes de Alto Risco Tratados por 
Intervenção Coronária Percutânea
Introdução: A prevenção secundária após intervenção coronária 
percutânea (ICP) é fundamental para melhorar a sobrevida livre 
de eventos e consiste principalmente no controle de fatores 
de risco. Analisou-se a prevenção secundária de pacientes de 
alto risco, incluídos prospectivamente no estudo Sequence 
Variation in Platelet Aggregation in Response to Clopidogrel 
and aspirin (SPARC). Métodos: Foram arrolados 187 pacientes 
consecutivos entre dezembro de 2009 e fevereiro de 2011, 
tratados por ICP com stent e avaliados em retornos ambula-
toriais de 30 dias, três meses, seis meses, e 12 meses quanto 
ao controle de hipertensão arterial, disglicemia, dislipidemia 
e tabagismo, e medidas terapêuticas respectivas. Resultados: 
Houve aumento significativo de pacientes com controle pres-
sórico (29%; P  =  0,02), que cessaram tabagismo (18%; P = 
0,003), e que receberam hipolipemiantes (19%; P <  0,0001) 
entre a internação para ICP e o primeiro retorno após o 
ABSTRACT
Background: Secondary prevention after percutaneous coronary 
intervention (PCI) is essential to increase event-free survival 
and consists mainly in risk factor control. We analyzed the 
secondary prevention of high-risk patients included prospec-
tively in the Sequence Variation in Platelet Aggregation in 
Response to Clopidogrel and aspirin trial (SPARC). Methods: 
From December 2009 to February 2011 we enrolled 187 
consecutive patients who were submitted to PCI with stent 
implantation and were evaluated in outpatient visits at 1, 3, 
6, and 12 months of follow-up for the control of hypertension, 
dysglycemia, hyperlipidemia and smoking and their respective 
therapeutic measures. Results: There was a significant increase 
in the number of patients with controlled hypertension (29%; 
P = 0.02), who stopped smoking (18%; P = 0.003), and 
received statins (19%; P < 0.0001) between the index PCI 
and the first follow-up visit. The risk factor control improve-
ment led to a decrease in the mean Framingham risk score 
(9.9%; P < 0.0001). During the 12 months follow-up the 
gains achieved at PCI admission were maintained for all risk 
factors. Conclusions: An important effect was observed on the 
index PCI admission with increased prescription of risk factor 
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control drugs and achievement of therapeutic goals. This study 
identifies a relevant opportunity window for risk factor control 
at the index admission, when substantial gains are observed 
and maintained. However, it also shows further efforts are 
required to expand the benefit of secondary prevention in the 
middle-term follow-up of patients treated by PCI.
 
 
 
 
 
 
 
 
 
DESCRIPTORS: Coronary artery disease. Angioplasty. Stents. 
Risk factors. Disease prevention.
METHODS
SPARC is a single-center study that enrolled consecu-
tive patients between December of 2009 and February 
of 2011, who underwent PCI with stenting and signed 
an informed consent. Patients were excluded when 
they were not treated with dual antiplatelet therapy 
with acetylsalicylic acid (ASA) and clopidogrel, as well 
as those aged < 18 years. The study was approved 
by the local and national ethics committees (CAAE. 
0153.0.004.000-09). 
Patients used a loading dose of clopidogrel of 300 
mg six to 12 hours before the procedure. The use of 
clopidogrel continued for at least 30 days after the PCI. 
In cases where drug-eluting stents (DES) were used, the 
use of clopidogrel continued for at least 12 months.8 
Baseline clinical and demographic characteristics are 
shown as means and standard deviations for continu-
ous variables and as percentages for discrete variables.
At the follow-up visits after 30 days, three months, 
six months, and 12 months, medication prescriptions 
and risk factor control were evaluated. The three-month 
follow-up could be cancelled at the discretion of the 
attending physician in cases of less complexity. If there 
was loss to follow-up, a telephone contact was made to 
substitute the 12-month consultation. Loss to follow-up 
was defined as patients who could not be contacted 
at the last consultation, either in person or by phone.
Data regarding the presence of factors risk for 
atherosclerosis (systemic arterial hypertension, dyslip-
idemia, dysglycemia, and smoking) and changes in 
prescription to control these risk factors were obtained 
during follow-up visits at specific outpatient clinics for 
patients treated with PCI at the institution. For second-
ary prevention, the BP goal was defined as systemic 
blood pressure < 130/80 mmHg;9 glycemic goal was 
defined as fasting glucose < 140 mg/dL and glycated 
procedimento. Esse melhora do controle de fatores de risco 
refletiu-se em redução do escore de risco de Framingham 
médio observado no mesmo período (9,9%; P  <  0,0001). 
Durante seguimento de até 12 meses o ganho atingido na 
internação para ICP se manteve para todos os fatores de ris-
co. Conclusões: Observou-se efeito importante relativamente 
à internação índice para ICP, com aumento da prescrição de 
medicamentos para controle de fatores de risco e alcance de 
metas. Esse estudo identifica relevante janela de oportunidade 
para priorização do controle de fatores de risco na internação 
inicial, quando expressivos são observados e mantidos. Mas 
também explicita que esforços adicionais são necessários para 
expandir o benefício da prevenção secundária no seguimento 
a médio prazo de pacientes tratados por ICP.
DESCRITORES: Doença da artéria coronariana. Angioplastia. 
Stents. Fatores de risco. Prevenção de doenças.
A ccording to data from the Department of Infor-matics of the Brazilian Unified Health System (Departamento de Informática do Sistema Único 
de Saúde – DATASUS), in the year 2012, cardiovascular 
diseases were the main cause of morbidity after the age 
of 39 years. In that year, they represented 20.95% of 
1,004,004 hospitalizations at this age range.1 Cardiovas-
cular diseases are also the leading cause of mortality in 
this same age group, with 641,424 deaths, represent-
ing 30.84% of the deaths recorded in the DATASUS 
information system in 2010.2
Percutaneous coronary intervention (PCI) has become 
the most used treatment in the spectrum of coronary 
heart disease, surpassing coronary artery bypass graft 
(CABG) surgery, wether to relieve angina symptoms, 
to improve quality of life, or to decrease mortality in 
different clinical contexts.3 In this context, there are 
patients with severe cardiovascular dysfunction due to 
the presence of coronary atherosclerotic disease and 
multiple associated risk factors. The secondary preven-
tion in these patients, after PCI treatment, becomes 
critically necessary to reduce subsequent adverse car-
diovascular events, requiring changes in lifestyle and 
control of risk factors with behavioral measures and 
medication.4 However, the integration of preventive 
measures in daily clinical practice is still poor,5 and 
the discontinuation of prescribed medications is com-
mon after acute events;6,7 moreover, it is very difficult 
to implement lifestyle changes.
The aim of this study was to evaluate the short- and 
mid-term control of risk factors in patients undergoing 
PCI. These patients were prospectively included in the 
single-center research project Sequence variation in 
Platelet Aggregation in Response to Clopidogrel and 
aspirin (SPARC), which investigates platelet aggregation 
and its determinant genes in a cohort treated by PCI, 
and is in its final phase of follow-up.
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hemoglobin < 7%;10 the acceptable low-density lipo-
protein cholesterol (LDL – cholesterol) goal was defined 
as LDL-cholesterol < 100 mg/dL.11
The use of the following medications was recorded 
at enrollment and at each follow-up consultation: ASA, 
clopidogrel, statins, diuretics, beta-blockers, calcium-
channel blockers, angiotensin-converting enzyme 
inhibitors, angiotensin receptor blockers II, nitrates, 
proton-pump inhibitors (omeprazole and similar drugs), 
and hypoglycemiants. To calculate the Framingham risk 
score (FRS) at enrollment, the lipid assessment used 
was that performed 30 days after PCI, due to changes 
in the lipid profile during acute coronary syndrome.12,13
Statistical analysis was performed with the program 
Stata 12.0 (Stata Corp. – College Station, USA). The 
achievement of goals and the prescription of medica-
tions were evaluated by analyzing the effect of the index 
hospitalization, the difference between admission and 
the first follow-up, and the effect of clinical follow-up, 
comparing trends between the first and last follow-up 
visits. Analysis of variance was used to compare the 
patients according to the follow-up visits and to as-
sess whether the therapeutic goals were achieved. The 
comparison of proportions between two follow-ups 
was tested using the McNemar test, and the trend of 
proportions during the follow-ups was tested using the 
chi-squared test2 for trends.14 The comparison of the FRS 
(non-parametric variable) was performed by Wilcoxon 
paired test. Statistical significance was set at P < 0.05.
The differences between patients who achieved 
the therapeutic goals and those who did not were also 
evaluated. The differences analyzed in this last assessment 
were: age, body mass index, gender, clinical indication, 
prior PCI, family history, peripheral arterial disease, 
prior CABG, prior myocardial infarction, and number of 
affected vessels. In this case, Bonferroni correction for 
multiple comparisons was used (P < 0.005). Analysis of 
the cardiac events was not performed, as the study was 
not designed to be able to compare these subgroups.
RESULTS
A total of 197 patients were enrolled during the 
study period. Seven of these patients (3.6%) did not 
undergo PCI with stent implantation, and three patients 
withdrew consent to participate after recruitment; thus, 
187 patients remained in the study. 
The patients’ mean age was 60.8 years, 68.4% (130) 
were males and 82.1% (151) considered themselves 
whites. Baseline characteristics and PCI data are shown 
in Table 1. Patients were followed after the PCI through 
standardized follow-up visits after 30 days, three, six, 
and 12 months. Attendance of patients at these follow-
ups was 95%, 56%, 86%, and 92%, respectively. A 
total of 7.5% of patients (14) were lost to follow-up. 
The loss to follow up occurred after the first follow-up 
TABLE 1  
Baseline data and characteristics of the percutaneous 
coronary intervention of patients enrolled in the study
Variable  ± 
Age, years 60.8 ± 9.7
Male gender, % 68.4
White, % 82.1
Body mass índex, Kg/m2 27.3 ± 4.9
Previous infarction, % 18.8
Previous percutaneous coronary 
intervention, %
10.3
Previous coronary artery bypass graft 
surgery, %
4.9
Peripheral arterial disease, % 4.3
Arterial hypertension, % 89.9
Dysglycaemia, % 40.6
Dyslipidaemia, % 73.3
Current smoking, % 40.5
Family history of coronary artery 
disease, %
36.2
Clinical presentation, %
Myocardial infarction with ST-segment 
elevation
24.6
Myocardial infarction without  
ST-segment elevation or high-risk 
unstable angina
28.9
Stable angina 42.8
Silent ischaemia 3.7
Multivessel, % 50.3
Treated vessel, %
Left coronary trunk 0.7
Left anterior descending artery 50
Left circumflex artery 21.1
Right coronary artery 36.1
Saphenous venous graft 0.7
Multivessel treatment, % 10.3
Drug-eluting stents, % 15.6
in 1.1%, after the second follow-up in 1.6%, and after 
the third follow-up in 4.8% of patients. In 12 patients 
(6.4%), the last consultation was performed only by 
telephone contact.
To evaluate the effect of treatment conducted in 
the outpatient clinic, data were collected on medication 
use and controllable risk factors, notably hypertension, 
dysglycemia, dyslipidemia, and smoking status. The 
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assessment was separated regarding the effect of the index 
hospitalization and outpatient follow-up, and regarding 
differences between the patients who had success in 
reaching a goal versus patients who failed to do so.
The baseline prevalence of patients diagnosed 
with systemic arterial hypertension was 89.9%, with a 
mean of 1.8 antihypertensive medications. At admission, 
49.1% of patients had controlled blood pressure, and 
at the first follow-up, 63.3%, representing a significant 
increase of 29% (P = 0.02). Table 2 shows the evolu-
tion of medication prescription and achievement of BP 
goal according to the follow-up visits. There was no 
difference in BP goal achievement between the first 
and last follow-ups (P = 0.3). 
The analysis of variance indicates that patients who 
did not achieve their BP goal were prescribed more 
antihypertensive medications when compared to those 
who did achieve their BP goal (P = 0.02), with interac-
tion with the date of follow-up (P = 0.049). Considering 
the interaction in the statistical model, the difference in 
prescription per follow-up consultation was calculated, 
which was statistically significant at the six-month and 
12-month follow-ups.
The prevalence of dysglycemia at study enrollment 
was 40.6%; 60.5% of these patients received drug 
treatment with oral hypoglycemiants or insulin. At 
the first follow-up, the use of oral hypoglycemiants 
or insulin in dysglycemic patients presented a non-
significant increase to 69.9% (P = 0.2). Glycemia was 
not measured at the index hospitalization. Table 3 
shows the glycemic control rate according to each 
follow-up and the percentage of use of hypoglyce-
miants of each subgroup. There was no difference in 
the achievement of therapeutic goals between the first 
and last follow-ups (P = 0.8).
TABLE 2  
Achievement of blood pressure (BP) goal according to follow-up visit and number of  
antihypertensive drugs per patient
Follow-up consultation
30 days 3 months 6 months 12 months
Yes No Yes No Yes No Yes No
Achievement of BP goal 63.3 36.7 58.4 41.6 54.7 45.3 60.7 39.3
Antihypertensives per patient 2.2 2.2 2.3 2.3 2.3 2.6 2.2 2.6
ANOVA (p) 0.8884 0.7745 0.0236 0.0026
BP, blood pressure; ANOVA, analysis of variance.
TABLE 3  
Achievement of glycemic goal in patients with dysglycemia according to follow-up visit and drug treatment 
Follow-up consultation
30 days 3 months 6 months 12 months
Yes No Yes No Yes No Yes No
Fasting glycemia < 140 mg/dL or HbA1c < 
7%, %
57.7 42.3 59.1 40.9 56.8 43.2 53.2 43.8
Medications, % 80 50 69.2 55.6 80 63.2 84 54.6
TABLE 4  
Achievement of LDL-cholesterol goal according to follow-up visit and statin treatment
Follow-up consultation
30 days 3 months 6 months 12 months
Yes No Yes No Yes No Yes No
LDL-cholesterol < 100 mg/dL, % 60.7 39.3 61.7 38.3 64.4 35.6 67 33
Statin use, % 97.1 86.4 89.7 83.3 96.6 96.9 94 97
LDL-cholesterol, low-density lipoprotein cholesterol.
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The analysis of variance shows higher prescription 
of oral hypoglycemiants and insulin among patients 
that reached the goal compared to those that did not 
(P = 0.004), with no significant interactions regarding 
follow-ups. 
The rate of patients who achieved the LDL-cholesterol 
goal is shown in Table 4; 60.7% achieved it at the first 
follow-up consultation. There is a non-significant trend 
of increase to 67%, in the last follow-up consultation (P 
= 0.5). Upon study enrollment, 76.6% of the patients 
were prescribed statins, which soon increased to 91.5% 
in the first follow-up, representing a significant increase 
of 19% (P < 0.0001). The rate of statin use did not vary 
with the follow-ups (P = 0.6). Among patients who did 
not reach the goal, there was a significant increase in 
statin prescription (P = 0.045) without a corresponding 
significant decrease in the number of patients who did 
not reach the goal.
Table 5 shows the prevalence of smoking at the 
30-day and 12-month follow-ups. In light of the defini-
tion used in the study, which only considers a patient 
an ex-smoker when he/she has ceased smoking for 
least 12 months, the prevalence of smoking at the 
30-day, three-month, and six-month follow-ups was 
the same as those at the study enrollment. However, 
it was observed that, at the 12-month follow-up, there 
was a decrease of 18% (P = 0.003) in the number of 
smokers; this reduction was significant compared to 
the initial prevalence of the study.
Comparisons were performed between the subgroups 
of patients who achieved the goals and those who did 
not. There were no significant differences between 
the subgroups of patients who achieved the BP, 
glycemia, and smoking cessation goals and those who 
did not. Patients who achieved the LDL-cholesterol 
goal, compared to those who did not, were mostly 
males (49.6% vs. 26.7%; P = 0.003) and entered the 
study with divergent indications for PCI (P < 0.001); 
they had more diagnoses of myocardial infarction with 
ST-segment elevation (38% vs. 14.8%), and less of stable 
angina (29.1 % vs. 52.8 %). 
The FRS was used to summarize the several risk 
factors controlled per patient in a single value. The pa-
tients’ mean FRS was 14.2 ± 6.4% at study enrollment 
, and 12.8 ± 6.1% at the 30-day follow-up. Thus, a 
significant relative decrease of 9.9% (P < 0.0001) was 
observed. There was no difference between the FRS at 
the 30-day and at the 12-month follow-up, which was 
12.3% ± 6.3%.
DISCUSSION
The control of risk factors for cardiovascular disease 
and complications is complex, and demand resources 
and exhaustive efforts. In spite of abundant scientific 
evidence demonstrating its benefits in multiple clinical 
settings, integration of strategies for actual effectiveness 
in daily clinical practice remains quite inadequate.5 
This study demonstrated a markedly positive ef-
fect associated with hospitalization for index PCI, 
increased prescription of medications indicated to 
control risk factors, achievement of goals, and decrease 
in smoking, as previously reported.15 Nevertheless, at 
the time of the PCI, only 50% of patients had blood 
pressure within the desired range. This increased to 
63% at the first follow-up. Smoking cessation, which 
was significant, representing 18% of patients, can be 
attributed temporally to the hospital, as patients are 
considered ex-smokers only after smoking cessation for 
at least 12 months. Considered a risk factor difficult 
to control, smoking cessation interconnects structured 
biopsychosocial factors, such as the habit of smoking 
and its associated practices, nicotine withdrawal syn-
drome, and the pleasure derived from this substance.16 
These characteristics are factors that place the chance 
of success at the first cessation attempt below 10%.17 
Additionally, there was an increase in the proportion 
of patients who achieved glycemic and LDL-cholesterol 
goals, although at non-significant statistical levels.
During follow-up, the essential effect of the outpatient 
visits was to maintain the gains obtained at the index 
hospitalization. There was no variation in the rates of 
goal achievement during the follow-ups. There was an 
increased prescription of antihypertensive drugs and statins 
to patients who did not achieve their goals compared 
to those who did. This fact raises questions regarding 
patient’s adherence to medications and recommended 
lifestyle changes.6 Considering that the patients treated 
at the outpatient clinic of this institution need and can 
make use of government programs for acquisition and 
supply of high-cost medications, free of charge, it is 
hypothesized that another barrier to the use of these 
drugs can result from excessive bureaucracy.
In the case of oral hypoglycemiants, an increase 
in the number of patients who achieved their goals 
was not observed, nor an increase in the prescription 
of oral hypoglycemiants or insulin. This may reflect not 
only the intrinsic difficulty of patients to follow specific 
behavioral measures for better control of dysglycemia, 
but also the occurrence of failures in nutritional counsel-
ling and physical activity.18 It is important to note that, 
in this study, the initial diagnosis of dysglycemia was 
based on the use of oral hypoglycemiants or insulin at 
TABLE 5  
Prevalence of smoking during follow-up visits
Follow-up consultation 30 days 12 months
Current smoker, % 42.2 34.6
Ex-smoker (> 1 year), % 28.7 36.2
Never smoked, % 29.2 29.2
Pavão et al. 
Control of Risk Factors for Post-PCI
Rev Bras Cardiol Invasiva. 
2013;21(2):121-7
126
the time of the PCI, while the levels of fasting glucose 
and HbA1c were also measured only at the follow-ups. 
Therefore, the initial high rate of patients with dysgly-
cemia must reflect the heterogeneous composition of 
this group of patients, and not only of patients with an 
established diagnosis of diabetes mellitus. 
Regarding the cardiovascular risk factors assessed 
in the study, no differences were observed between 
groups of patients who achieved or did not achieve 
the goals established to control those factors, except 
for the comparison of patients who achieved the LDL-
cholesterol goal versus those who did not. It should be 
noted that this subgroup of patients had a higher rate 
of PCI indication, due to acute myocardial infarction 
and lower rate of PCI indication due to stable angina. 
In fact, in general, at the 30-day follow-up, the mean 
LDL-cholesterol of patients who suffered myocardial 
infarction with ST-segment elevation was 83.7 ± 3.7 
mg/dL, significantly lower than that of patients who had 
a diagnosis of stable angina, with 107 ± 4.7 mg/dL (P 
= 0.001). The effect of the reduction in apolipoprotein 
levels usually occurs in the first days after the infarc-
tion, and is not expected in subsequent measurements 
of cholesterol levels 30 days after the event. It can be 
assumed that, due to the initial severity of the event, 
these patients became more motivated regarding the 
treatment than patients with PCI indicated due to stable 
angina. In this context, is interesting to observe that 
incremental programs of secondary prevention stimulus 
after acute myocardial infarction, such as assistance 
through telephone contact, did not result in clinical 
gain nor appear to be cost-effective, compared with 
the usual preventive program.19
In this study, a relative decrease of 10% was ob-
served in FRS between enrollments and at the 30-day 
follow-up, and its maintenance at subsequent follow-ups. 
Since the FRS includes in its calculation the risk factors 
evaluated in this study, despite having been created to 
assess the risk of primary cardiac events, it is suitable for 
the present context, as it allows for the use of a single 
value to represent all the preventive efforts performed. 
This fact not only demonstrates the importance of the 
index treatment, but also that there was no subsequent 
score variation during outpatient follow-up.
The increased survival, reduction of other severe 
adverse events, and quality of life improvement are not 
restricted to the success of percutaneous treatment in 
itself. In contrast, such results, if achieved, also reflect 
the effect of good quality and periodic medical follow-up 
in an attempt to overcome the difficulties inherent to the 
recommendations, changes in lifestyle, and adherence to 
the prescribed medications. In patients treated with PCI, 
the increase in the achievement of goals related to risk 
factor control is expected when assistance is obtained 
from specific support groups provided by other health 
professionals, with introduction of specific treatments 
and multidisciplinary guidance, aiming at emphasizing 
the importance of medications. It is also noteworthy 
that, compared to the more traumatic procedure of 
CABG, patients treated with PCI appears to be more 
likely to adhere to secondary prevention, also due to 
greater adherence to medication use.20
CONCLUSIONS
The present study can be used as a basis to guide 
the initial measures of a secondary prevention program 
after PCI, to generate hypotheses for implementing 
methods and therapies aimed at better control of risk 
factors, starting with its results as guides for current 
practices, as well as to serve as a historical control 
group in future clinical experimental groups for studies 
that measure effectiveness.
In essence, it identifies an excellent opportunity 
to prioritize the control of risk factors at the initial 
hospitalization related to the PCI, when significant gains 
are observed and maintained. However, it can also be 
observed that additional efforts are needed to expand 
the benefit of secondary prevention in the middle-term 
follow-up of patients treated with PCI.
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